Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2022-08-25 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
第三届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding several agenda items, including approval of the 2022 half-year report and related matters. It references other documents such as the half-year report and a special report on fundraising use, but does not contain the actual financial data or full reports itself. The document is relatively short (1662 characters) and serves as an official meeting resolution announcement rather than a full financial report or detailed management discussion. It also includes voting results and procedural details of the Supervisory Board meeting. This fits best with the category of Regulatory Filings (RNS), as it is a formal regulatory announcement of meeting resolutions and approvals without the full report content.
2022-08-25 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "内蒙古大唐药业股份有限公司 2022 年半年度报告" which translates to "Inner Mongolia Grand Pharmaceutical Co., Ltd. 2022 Semi-Annual Report." It contains detailed financial data, including income statements, balance sheets, cash flow, and management discussion of financial performance for the first half of 2022 (January 1 to June 30, 2022). The document includes sections on company overview, accounting data, business review, risk factors, and financial analysis. It explicitly states it is a "半年度报告" (half-year report), which corresponds to an Interim / Quarterly Report. The document is comprehensive, with actual financial statements and substantive financial data, not merely an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-25 Chinese
内蒙古上都律师事务所关于内蒙古大唐药业股份有限公司2020年第一期股权激励计划部分限制性股票回购注销之法律意见书
Regulatory Filings
2022-08-25 Chinese
关于拟修订公司章程公告
Governance Information Classification · 95% confidence The document is an announcement regarding the proposed amendments to the company's Articles of Association (公司章程). It details changes in registered capital and share capital due to a share repurchase and cancellation related to an equity incentive plan. The document includes a board resolution reference and states that the amendments will be submitted to the shareholders' meeting for approval. This is a governance-related announcement about internal company rules and capital structure changes but does not contain full financial statements or detailed financial performance data. It is not a full annual or interim report, nor is it a simple notice of dividend or voting results. The content fits best under Governance Information (CGR) as it relates to company bylaws and governance documents.
2022-08-25 Chinese
关于公司2020 年第一期股权激励计划部分限制性股票回购注销的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the repurchase and cancellation of restricted shares under the company's 2020 equity incentive plan. It details the board and supervisory approvals, the number of shares repurchased, the price, and the impact on share capital and structure. It is not a full financial report, earnings release, or management discussion, but a specific corporate action related to share repurchase and cancellation. This fits the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares. The document length is about 2412 characters, which is consistent with an announcement rather than a full report.
2022-08-25 Chinese
关于向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Inner Mongolia Datang Pharmaceutical Co., Ltd. regarding its application to a bank for a comprehensive credit line. It details the board meeting resolution approving the credit application, the necessity of the credit for business operations, and the impact on the company. There are no financial statements or detailed financial data presented. The document is about a financing activity (applying for a credit facility) rather than a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification, so it is not RPA or RNS.
2022-08-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.